hrcak mascot   Srce   HID

Acta Pharmaceutica, Vol. 60 No. 4, 2010.

Pregledni rad
https://doi.org/10.2478/v10007-010-0039-2

Razvoj selektivnih biofarmaceutika iz glikoproteina E i I iz Herpes simplex virusa tipa 1 koji blokiraju neutralizaciju onkolitskih virusa posredovanu antitijelima

SEPTIMIU BUCURESCU   ORCID icon orcid.org/0000-0002-5333-9361 ; “Rhoen Klinikum AG” Hospital, 97616 Bad Neustadt ad Saale, Germany

Puni tekst: engleski, pdf (59 KB) str. 407-413 preuzimanja: 226* citiraj
APA 6th Edition
BUCURESCU, S. (2010). Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses. Acta Pharmaceutica, 60 (4), 407-413. https://doi.org/10.2478/v10007-010-0039-2
MLA 8th Edition
BUCURESCU, SEPTIMIU. "Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses." Acta Pharmaceutica, vol. 60, br. 4, 2010, str. 407-413. https://doi.org/10.2478/v10007-010-0039-2. Citirano 16.02.2019.
Chicago 17th Edition
BUCURESCU, SEPTIMIU. "Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses." Acta Pharmaceutica 60, br. 4 (2010): 407-413. https://doi.org/10.2478/v10007-010-0039-2
Harvard
BUCURESCU, S. (2010). 'Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses', Acta Pharmaceutica, 60(4), str. 407-413. doi: https://doi.org/10.2478/v10007-010-0039-2
Vancouver
BUCURESCU S. Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses. Acta Pharm. [Internet]. 2010 [pristupljeno 16.02.2019.];60(4):407-413. doi: https://doi.org/10.2478/v10007-010-0039-2
IEEE
S. BUCURESCU, "Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses", Acta Pharmaceutica, vol.60, br. 4, str. 407-413, 2010. [Online]. doi: https://doi.org/10.2478/v10007-010-0039-2

Sažetak
Terapija karcinoma će u budućnosti biti na molekularnoj razini. Bit će moguće promijeniti, blokirati ili uništavati stanice ciljanim utjecanjem na molekularne promjene koje vode do karcinogeneze. Uništavanje stanica karcinoma moći će se ostvariti pomoću onkolitskih virusa. U pomoćnoj terapiji karcinoma moći će se koristiti glikoproteini E i I iz Herpes simplex virusa tipa 1 koji blokiraju neutralizaciju onkolitskih virusa posredovanu antitijelima, čime se povećavaju šanse da onkolitski virusi unište stanice karcinoma in vivo.

Ključne riječi
terapija karcinoma; glikoproteini E i I Herpes simplex virusa tipa 1; neutralizacija onkolitskih virusa posredovana antitijelima

Hrčak ID: 59808

URI
https://hrcak.srce.hr/59808

[engleski]

Posjeta: 433 *